Rutgers University, RWJBarnabas Health, and Hiroshima University have signed a letter of intent (LOI) creating a joint effort to advance cancer research and education between New Jersey and Japan. A memorandum of understanding (MOU) between Rutgers University and Hiroshima University was also signed during the Choose New Jersey governor-led economic mission to East Asia.
“With today’s ceremony, we will establish a new, cross-continental partnership — one that will enable our top minds in New Jersey to engage and exchange ideas with researchers here in Hiroshima,” said Murphy. “In the years to come, I am confident that this partnership will lead to important breakthroughs, especially when it comes to caring for cancer patients in New Jersey, Japan, and around the world.”
“In a world where boundaries are becoming increasingly blurred, it’s collaborations like these that remind us of the power of knowledge and the pursuit of innovation are worthy endeavors,” said U.S. Ambassador to Japan Rahm Emanuel.
The LOI was signed Sunday, October 15, 2023, by Antonio M. Calcado, executive vice president and chief operation officer; Rutgers University, Mark E. Manigan, president and CEO, RWJBarnabas Health; and Mitsu Ochi, M.D., Ph.D., president, Hiroshima University.
By signing the LOI, the three institutions agree to future collaboration on digestive tract cancer clinical trials. The agreement also creates an exchange between top researchers and students, fostering inquiry and innovation by offering access to new technologies, research methods, and opportunities for mutual advancement in New Jersey and Japan’s health sciences industries.
The agreement will allow RBHS, RWJBarnabas Health, and Hiroshima University researchers and undergraduate and graduate students to study, conduct, and present research across the respective institutions, creating new academic, business, and research and development opportunities in New Jersey and Japan.
“This historic collaboration between Rutgers University and RWJBarnabas Health with the Graduate School of Biomedical and Health Sciences of Hiroshima University is part of a broader initiative to expand Rutgers Health’s research and clinical strengths globally,” said Brian Strom, chancellor, Rutgers Biomedical and Health Sciences.
Hiroshima University stands one of the top comprehensive research universities in Japan, covering a wide spectrum of academic disciplines. Hiroshima University is at the forefront of cutting-edge research in diverse fields such as ‘Knotted Chiral Meta Matter’, ‘Genomics’, ‘Brain Sciences’, and ‘Nanodevices’. In the field of medicine, we are committed to advancing medical care and contributing to community medicine. The university achieved notable recognition,securing 10th in Japan in a 2021 ranking of universities based on the total number of clinical medical papers published in Q1 journals.
“Research is at the heart of New Jersey’s standing as a leading global innovation hub,” said Wesley Mathews, president and CEO of Choose New Jersey. “Today, we take another step in strengthening our state’s innovation ecosystem with a leading Japanese research university.”
To access more business news, visit NJB News Now.Related Articles: